These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 11102421)

  • 1. Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents.
    Aller AI; Martín-Mazuelos E; Gutiérrez MJ; Bernal S; Chávez M; Recio FJ
    J Antimicrob Chemother; 2000 Dec; 46(6):997-1000. PubMed ID: 11102421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.
    Warnock DW; Johnson EM; Rogers TR
    J Antimicrob Chemother; 1998 Sep; 42(3):321-31. PubMed ID: 9786472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multisite reproducibility of the Etest MIC method for antifungal susceptibility testing of yeast isolates.
    Pfaller MA; Messer SA; Bolmström A; Odds FC; Rex JH
    J Clin Microbiol; 1996 Jul; 34(7):1691-3. PubMed ID: 8784571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of broth dilution and semisolid agar dilution for in vitro susceptibility testing of Cryptococcus neoformans.
    Del Poeta M; Barchiesi F; Morbiducci V; Arzeni D; Marinucci G; Ancarani F; Scalise G
    J Chemother; 1994 Jun; 6(3):173-6. PubMed ID: 7983499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
    Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
    Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
    J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of media on growth rate and susceptibility testing of Cryptococcus neoformans.
    St-Germain G; Dion C
    Mycoses; 1996; 39(5-6):201-6. PubMed ID: 8909030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Etest method for determining voriconazole and amphotericin B MICs for 162 clinical isolates of Cryptococcus neoformans.
    Maxwell MJ; Messer SA; Hollis RJ; Diekema DJ; Pfaller MA
    J Clin Microbiol; 2003 Jan; 41(1):97-9. PubMed ID: 12517832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of NCCLS microdilution method and Etest in antifungal susceptibility testing of clinical Trichosporon asahii isolates.
    Arikan S; Hasçelik G
    Diagn Microbiol Infect Dis; 2002 Jun; 43(2):107-11. PubMed ID: 12088616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of Etest and broth microdilution method (AFST-EUCAST) for trends in antifungal drug susceptibility testing of Brazilian Cryptococcus neoformans isolates.
    Dias ALT; Matsumoto FE; Melhem MSC; da Silva EG; Auler ME; de Siqueira AM; Paula CR
    J Med Microbiol; 2006 Dec; 55(Pt 12):1693-1699. PubMed ID: 17108273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
    Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
    Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.
    Souza LK; Fernandes Ode F; Kobayashi CC; Passos XS; Costa CR; Lemos JA; Souza-Júnior AH; Silva Mdo R
    Rev Inst Med Trop Sao Paulo; 2005; 47(5):253-6. PubMed ID: 16302107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of antifungal MICs for yeasts obtained using the EUCAST method in a reference laboratory and the Etest in nine different hospital laboratories.
    Dannaoui E; Paugam A; Develoux M; Chochillon C; Matheron J; Datry A; Bouges-Michel C; Bonnal C; Dromer F; Bretagne S
    Clin Microbiol Infect; 2010 Jul; 16(7):863-9. PubMed ID: 19778296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Etests and Vitek 2 ® to broth microdilution for the susceptibility testing of Cryptococcus neoformans.
    Mahabeer Y; Chang CC; Naidu D; Dorasamy A; Lewin S; Ndung'u T; Moosa MY; French M; Mlisana K; Coovadia Y
    Diagn Microbiol Infect Dis; 2014 Dec; 80(4):294-8. PubMed ID: 25277745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Sensititre YeastOne colorimetric microdilution panel and the NCCLS broth microdilution method for antifungal susceptibility testing against Candida species.
    Bernal S; Aller AI; Chávez M; Valverde A; Serrano C; Gutiérrez MJ; Quindós G; Martín Mazuelos E
    Chemotherapy; 2002 Mar; 48(1):21-5. PubMed ID: 11901252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility of Cryptococcus neoformans by the NCCLS microdilution and Etest methods using five defined media.
    Petrou MA; Shanson DC
    J Antimicrob Chemother; 2000 Nov; 46(5):815-8. PubMed ID: 11062205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of a new colorimetric assay with the NCCLS broth microdilution method (M-27A) for antifungal drug MIC determination.
    Li RK; Elie CM; Clayton GE; Ciblak MA
    J Clin Microbiol; 2000 Jun; 38(6):2334-8. PubMed ID: 10834998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.
    Dannaoui E; Abdul M; Arpin M; Michel-Nguyen A; Piens MA; Favel A; Lortholary O; Dromer F;
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2464-70. PubMed ID: 16801427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative evaluation of Fungitest-, Neo-Sensitabs- and M27T-NCCLS broth microdilution methods for antifungal drug susceptibility testing of Candida species and Cryptococcus neoformans.
    Swinne D; Raes-Wuytack C; Van Looveren K; Desmet P
    Mycoses; 1999; 42(4):231-7. PubMed ID: 10424089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of Neo-Sensitabs tablet diffusion assay results on three different agar media with CLSI broth microdilution M27-A2 and disk diffusion M44-A results for testing susceptibilities of Candida spp. and Cryptococcus neoformans to amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole.
    Espinel-Ingroff A; Canton E; Gibbs D; Wang A
    J Clin Microbiol; 2007 Mar; 45(3):858-64. PubMed ID: 17215342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.